USFDA Completes Follow-up Inspection at Cipla's Pithampur Manufacturing Facility
Cipla Limited has completed the follow-up inspection by the United States Food and Drug Administration (USFDA) at its manufacturing facility located in Pithampur, India. The inspection took place from August 17, 2026, to August 25, 2026.Following the conclusion of the inspection, the company received seven inspectional observations documented in Form 483.
Cipla has committed to working closely with the USFDA and plans to address these observations comprehensively within the stipulated timeline. The company intends to ensure all concerns raised during the inspection are fully mitigated.
CIPLA Stock Price Movement
Shares of Cipla Limited settled lower today after shedding 1.11%, closing the session at ₹1422. The stock saw a total traded volume of 799,235 shares during post-market trading.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.